



For more information contact:

Mattson Communications, Inc.

Kathy Mattson

312-988-9352

kathy@mattsonpr.com

TransMolecular, Inc.

Alyssa Vanderpool

617-995-3050 ext. 302

vanderpool@transmolecular.com

TransMolecular Relocates Headquarters to Cambridge, MA to Accommodate Next Phase of Growth

Cambridge, Mass. – November 15, 2005 – TransMolecular, Inc., a biotechnology company focused on cancer drug development, today announced the relocation of its headquarters to Cambridge from Birmingham, Alabama. The company now occupies approximately 4400 square feet of leased office and clinical laboratory space located at The Riverside Technology Center at 840 Memorial Drive in Cambridge.

“TransMolecular’s relocation and expansion of our headquarters is testimony to the fact that we have aggressive corporate and clinical goals,” said E. Michael Egan, President and CEO of TransMolecular. “The new offices and laboratory space will provide us the necessary space to immediately expand our clinical operations, as well as our scientific team, regulatory affairs, quality and manufacturing staff.”

TransMolecular continues to aggressively recruit and enroll patients in the Phase II Clinical Trials of ¹³¹I-TM-601 in adult patients with recurrent high-grade glioma. ¹³¹I-TM-601 is a radiopharmaceutical containing a synthetic version of chlorotoxin, a substance derived from scorpion venom. Chlorotoxin, or TM-601, specifically seeks out and binds to a receptor expressed on tumor cells, but not on normal cells. It acts as the guidance system that delivers a radioactive payload to its target, killing the tumor cells and minimizing collateral damage to normal cells. ¹³¹I-TM-601 has received Orphan Drug and Fast Track Development Program status from the FDA and Phase II Clinical Trials

are being conducted across the country.

TransMolecular will maintain clinical operations in Birmingham to ensure that enrollment in the Phase II studies proceed without interruption.

About TransMolecular, Inc.

TransMolecular, Inc. is a privately held, venture capital backed biotechnology company committed to discovering, developing and commercializing novel and proprietary products to diagnose and treat diseases having inadequate pharmaceutical alternatives, including cancer and pain. Research on TransMolecular's product pipeline based on a small peptide derived from scorpion venom that is expected to be useful in treating a wide variety of cancers is ongoing. More information can be found at www.transmolecular.com.

####